Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study examines whether oral magnesium treatment inhibits platelet-dependent thrombosis (PDT) in patients with coronary artery disease (CAD).

Who Took Part

The abstract describes 42 patients taking part.

By PubMed's age tags, the people studied were older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

In the crossover set-up each of the patients took both Vitamin D, K2, Magnesium and Zinc and the comparison in turn, acting as their own control.

PDT, platelet aggregation, platelet P-selectin flow cytometry, monocyte tissue factor procoagulant activity (TF-PCA), and adhesion molecule density were assessed before and after each phase.

PDT was evaluated by an ex vivo perfusion model using the Badimon chamber.

What Was Measured

The subject headings attached to it are Antacids, Blood Platelets, Coronary Disease, Coronary Thrombosis, Dietary Supplements, Lipids and Magnesium.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 42 patients.

The publication is from 1999 (The American journal of cardiology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.